Beacon raises $132M+ to bring AI-driven sleep diagnostics to masses
The device aims to bring precision neuroscience into clinical trials, accelerating drug development
The device aims to bring precision neuroscience into clinical trials, accelerating drug development
The new capital is expected to fund the company through 2029
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Subscribe To Our Newsletter & Stay Updated